📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 18:16
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
30 announcements match the current filters (relevance ≥ 5).
Natural Capsules revises preferential issue terms; to raise ₹10.01 Cr from promoter at ₹178/share
Natural Capsules Limited has issued a corrigendum to its EGM notice for the meeting scheduled on September 9, 2026, revising the issue price and quantity for its proposed preferential issue following exchange queries and a fresh valuation report. The company plans to issue 1,12,500 equity shares (aggregating ₹2.00 Cr) and 4,50,000 convertible warrants (aggregating ₹8.01 Cr) at ₹178 per share/warrant to promoter Sunil Laxminarayan Mundra. Total capital infusion stands at ₹10.01 Cr (approx. 4.5% of current market cap), increasing total promoter holding from 50.92% to 53.44% on a fully diluted basis.
Confidence: HIGH
What changedNatural Capsules modified the preferential allotment terms, fixing the price at ₹178 per share/warrant for 1.125 lakh equity shares and 4.50 lakh convertible warrants following BSE/NSE queries.
Why it mattersProvides ₹10.01 Cr of direct equity liquidity from the promoter to support operations and API ramp-up amid recent quarterly losses.
Issue price: ₹178 per shareTotal fundraise: ₹10.01 CrFundraise vs Market Cap: ~4.5%Promoter post-issue stake: 53.44%EGM Date: September 09, 2026
📅 Short termShareholder approval at the September 9, 2026 EGM and subsequent in-principle exchange approvals will be key milestones over the coming weeks.
📈 Long termPromoter capital infusion signals internal commitment, but sustained turnaround depends on the API segment reaching break-even capacity utilization.
⚠ Risk flags
- Preferential price of ₹178 is below the current market price of ₹216.20.
- Dilution of public shareholding from 49.08% to 46.56%.
Key Highlights
Revised issue price set at ₹178 per share and warrant based on valuation report dated August 31, 2026.
Issuance of 1,12,500 equity shares (₹2.00 Cr) and 4,50,000 convertible warrants (₹8.01 Cr), totaling ₹10.01 Cr.
Allotment designated entirely to promoter Sunil Laxminarayan Mundra, increasing his stake from 5.79% to 10.61%.
Total promoter group stake will increase from 50.92% to 53.44% post-dilution.
EGM scheduled for September 09, 2026 with relevant pricing date fixed as August 10, 2026.
👀 What to Watch
Track voting results from the EGM on September 9, 2026, stock exchange listing approvals, and subsequent deployment of funds into scaling the API division.
Natural Capsules Revises ₹10.01 Cr Promoter Preferential Issue at ₹178/Share
Natural Capsules' board approved a revised preferential issue to promoter Sunil L Mundra following queries from BSE and NSE. The issue comprises 1,12,500 equity shares at ₹178 each (raising ₹2.00 Cr) and 4,50,000 convertible warrants at ₹178 each (raising ₹8.01 Cr), totaling ₹10.01 Cr. Upon full conversion, the promoter's holding will increase from 5.79% to 10.61%. The issue is subject to shareholder approval at the EGM scheduled for September 9, 2026.
Confidence: HIGH
What changedThe board revised the preferential issue terms (pricing fixed at ₹178/share and quantity adjusted) based on a fresh valuation report following exchange queries.
Why it mattersProvides ₹10.01 Cr in equity funding from the promoter to support operations amid recent quarterly losses, while materially increasing the promoter's skin in the game.
Total fundraise value: ₹10,01,25,000Issue price per share/warrant: ₹178Fundraise vs Market Cap: ~4.7%Pre-issue promoter holding: 5.79%Post-conversion promoter holding: 10.61%EGM Date: September 09, 2026
📅 Short termApproval at the September 9 EGM and subsequent receipt of ₹2.00 Cr upfront for shares plus 25% warrant application money (~₹2.00 Cr) will provide immediate liquidity.
📈 Long termIncreased promoter commitment aligns management incentives, though sustained long-term turnaround hinges on API commercial scale-up and reaching cash break-even.
⚠ Risk flags
- Equity dilution of minority shareholders
- Warrant conversion risk if remaining 75% funds are not exercised within 18 months
Key Highlights
Preferential issuance of 1,12,500 equity shares at ₹178 per share aggregating to ₹2,00,25,000
Issuance of 4,50,000 convertible warrants at ₹178 per warrant aggregating to ₹8,01,00,000
Total capital to be raised from promoter Sunil L Mundra is ₹10.01 Cr (~4.7% of ₹212 Cr market cap)
Promoter shareholding of Sunil L. Mundra will increase from 5.79% (6,02,290 shares) to 10.61% (11,64,790 shares) post full conversion
25% upfront warrant subscription (₹44.50 per warrant) with an 18-month conversion window
👀 What to Watch
Track shareholder approval at the upcoming EGM on September 9, 2026, and the subsequent inflow of funds to support working capital or API scale-up.
Natural Capsules Calls EGM for ₹2 Cr Preferential Equity Issue to Promoter at ₹160
Natural Capsules Limited has issued a notice for an Extraordinary General Meeting (EGM) on September 09, 2026, to approve preferential allotments. The company plans to issue 1,25,000 equity shares at ₹160.00 per share to promoter Sunil Laxminarayan Mundra, raising ₹2.00 crore, alongside convertible warrants. The issue price of ₹160.00 is at a premium to the current market price of ₹148.30. The fundraise quantum is modest, representing approximately 1.3% of the company's current market cap of ₹153 crore.
Confidence: HIGH
What changedNatural Capsules has formally convened an EGM to approve a preferential equity and warrant issuance to its promoter.
Why it mattersPromoter infusion at a premium (₹160 vs ₹148.3 CMP) signals promoter backing amid recent quarterly losses, though the capital addition (₹2 Cr) is small relative to TTM revenue of ₹177 Cr.
Equity shares to be allotted: 1,25,000Issue price per share: ₹160.00Total equity issue size: ₹2.00 CrIssue size vs Market Cap: ~1.3%EGM date: September 09, 2026Relevant date: August 10, 2026
📅 Short termShareholders will vote at the September 09 EGM; market sentiment is typically supported by promoter buying at a premium to market price.
📈 Long termLimited direct balance sheet impact due to the small size (₹2 Cr), though it supports liquidity as the company works to scale its API and capsule lines toward profitability.
⚠ Risk flags
- Minor equity dilution
- Company is currently loss-making at TTM net profit of ₹-25 Cr
Key Highlights
Preferential allotment of 1,25,000 equity shares at ₹160.00 per share
Total equity tranche fundraise size of ₹2.00 crore
Allotment proposed entirely to promoter Sunil Laxminarayan Mundra
EGM scheduled for September 09, 2026; relevant pricing date set as August 10, 2026
👀 What to Watch
Track the shareholder voting outcome at the EGM on September 09, 2026, and watch for subsequent allotment disclosures within 15 days of approval.
Natural Capsules Q1 FY27: Revenue up 8% YoY to ₹48.71 Cr; API Segment Scaling Progresses
Natural Capsules Limited (NCL) reported a Q1 FY27 revenue of ₹48.71 Cr, an 8% YoY increase, though it remains loss-making with a PAT of ₹-5.74 Cr. The company is strategically converting HPMC capsule lines to gelatin due to erratic US demand and duty uncertainties to protect margins. The API segment is showing operational progress with the commencement of contract manufacturing for Fermbox Bio and gram-scale synthesis of Prednisolone. Management is targeting WHO GMP certification by Q2 FY27 to facilitate scaling of the API business, which currently requires significantly higher utilization to reach cash break-even.
Confidence: HIGH
What changedThe company is pivoting its HPMC capacity to gelatin lines to optimize utilization and has initiated its first contract manufacturing batches in the API segment.
Why it mattersThe API division is currently the primary driver of losses; achieving commercial scale and regulatory approvals is critical for the company's turnaround and long-term profitability.
Q1 FY27 Revenue: ₹48.71 CrQ1 FY27 PAT: ₹-5.74 CrEBITDA Margin: 2.30%Installed Capacity: 20.25 BCPARevenue vs TTM Revenue: 28%
📅 Short termThe market will likely focus on the recovery of sales deferred by the ERP implementation and the impact of HPMC-to-gelatin line conversions on margins in the next quarter.
📈 Long termStructural growth depends on the successful transition to high-value steroidal APIs and regulated market exports, which are currently hampered by technical scaling challenges and trade regulations.
⚠ Risk flags
- Continued quarterly losses
- High utilization required for API break-even
- Erratic US demand for HPMC capsules
- Geopolitical headwinds affecting African exports
Key Highlights
Q1 FY27 Revenue reached ₹48.71 Cr, representing approximately 28% of TTM revenue.
EBITDA grew 251% YoY to ₹1.12 Cr, although margins remain thin at 2.30%.
Total capsule capacity stands at 20.25 billion units per annum as of FY26.
API division requires 25-30% utilization (approx. ₹100 Cr revenue) to reach cash break-even.
Export revenue contributed 28.94% to the total turnover in FY26.
👀 What to Watch
Monitor the progress of the WHO GMP audit expected in Q2 FY27 and the successful commercial production of the first backward-integrated Prednisolone batch by September-end.
Rs 48.71 Cr Revenue in Q1 FY27; API Segment Progresses with New CMO Deals
Natural Capsules reported Q1 FY27 revenue of Rs 48.71 Cr, a 25% YoY increase, though it remains loss-making with a PAT loss of Rs 5.74 Cr. The company is pivoting its HPMC capacity back to gelatin due to US market uncertainty and duty structures, converting one line immediately with another to follow. The API segment is showing operational progress with new contract manufacturing (CMO) agreements and the appointment of a new COO from Shilpa Medicare. A WHO GMP audit for the API facility is expected by the end of Q2 FY27, which is critical for scaling international sales.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, showing YoY revenue growth but continued net losses, alongside a strategic shift to convert HPMC lines to gelatin to protect margins.
Why it mattersThe company is currently loss-making (TTM PAT -Rs 19 Cr) and is relying on the API segment and CMO deals to reach break-even, while managing volatility in its core capsule business.
Q1 Revenue: Rs 48.71 CrQ1 PAT: Rs -5.74 CrRevenue Growth (YoY): 25%EBITDA Margin: 2.30%API Break-even Revenue Target: Rs 100 Cr
📅 Short termThe stock may remain range-bound as the market weighs the 25% YoY revenue growth against the continued net loss and the strategic retreat in the HPMC segment.
📈 Long termStructural turnaround depends on the successful commercialization of the API facility and achieving WHO GMP certification to access regulated markets.
⚠ Risk flags
- Continued net losses
- US market uncertainty for HPMC capsules
- High capacity utilization required for API break-even
Key Highlights
Revenue grew 25% YoY to Rs 48.71 Cr, representing approximately 28% of TTM revenue.
EBITDA margins stood at 2.30%, a slight improvement of 159 bps YoY despite input cost pressures.
ERP implementation at quarter-end resulted in 5 days of sales being deferred into Q2 FY27.
API segment leadership strengthened with a new COO having 30+ years of industry experience.
Conversion of HPMC lines to gelatin initiated to optimize capacity utilization amid erratic US demand.
👀 What to Watch
Monitor the outcome of the WHO GMP audit scheduled for Q2 FY27 and the volume ramp-up in the API segment, which requires ~Rs 100 Cr revenue for cash break-even.
Natural Biogenex Appoints K. H. Honneshaiah as COO to Lead API Operations
Natural Capsules Limited (NCL) has appointed Mr. K. H. Honneshaiah as the Chief Operating Officer (COO) of its material unlisted subsidiary, Natural Biogenex Private Limited. This appointment is significant as the subsidiary manages the steroidal API facility, which currently requires a capacity utilization of 25-30% (approx. ₹100 cr revenue) to reach cash break-even. The new COO brings 36 years of experience in regulated API manufacturing and greenfield scaling, addressing a critical leadership need for a segment that has contributed to NCL's TTM net loss of ₹19 cr.
Confidence: HIGH
What changedNatural Capsules has hired a veteran operations leader to head its material API subsidiary, Natural Biogenex.
Why it mattersThe API segment is the company's primary growth engine but also its largest current financial drag; veteran leadership is essential to transition from lab-scale to profitable commercial production.
COO Experience: 36 yearsAPI Break-even Revenue Target: ₹100 crTTM Net Profit: ₹-19 crMarket Cap: ₹161 cr
📅 Short termThe market may view this as a proactive step to address operational bottlenecks in the API division, potentially stabilizing sentiment after a 25% share price decline over 12 months.
📈 Long termIf the new COO successfully scales the API facility to the required 25-30% utilization, it could structurally pivot the company from losses to profitability.
⚠ Risk flags
- Execution risk in scaling complex steroidal API production
- High current cash burn in the subsidiary
Key Highlights
Appointment of Mr. K. H. Honneshaiah as COO of Natural Biogenex Private Limited effective August 12, 2026
New COO brings 36 years of experience in regulated API, Polymers, Peptides, and CDMO operations
Subsidiary is central to NCL's target of achieving a ₹225 cr topline for FY26
API division currently faces quarterly losses of ~₹10 cr due to low utilization levels
Leadership change specifically targets the scaling of regulated pharma plants and greenfield capacity
👀 What to Watch
Investors should monitor the next two quarters for improvements in API capacity utilization and a reduction in quarterly losses, which have recently averaged ₹5-7 cr per quarter.
₹10 Cr Promoter Fundraise Approved Amidst ₹5.74 Cr Q1 Net Loss
Natural Capsules Limited (NCL) reported a consolidated net loss of ₹5.74 Cr for Q1 FY27, compared to a loss of ₹5.58 Cr in the same quarter last year. While revenue grew 7.7% YoY to ₹48.71 Cr, the API segment remains a significant drag, posting a loss of ₹8.04 Cr on revenue of just ₹5.69 Cr. To bolster the balance sheet, the board approved a ₹10 Cr fundraise through a preferential issue of equity and warrants to promoters at ₹160 per share, which is a slight premium to the current market price. This infusion represents approximately 6.2% of the company's current market capitalization.
Confidence: HIGH
What changedThe company has initiated a ₹10 Cr capital infusion from promoters and reported Q1 FY27 results showing continued operational stress in the API division.
Why it mattersThe promoter funding provides a necessary liquidity cushion as the company struggles with losses and high interest costs while trying to scale its complex steroidal API and HPMC capsule lines.
Fundraise vs Market Cap: ~6.2%Q1 Net Loss: ₹5.74 CrAPI Segment Revenue: ₹5.69 CrAPI Segment Loss: ₹8.04 CrIssue Price per Share: ₹160
📅 Short termThe stock may see support from the promoter's decision to infuse capital at a premium (₹160 vs CMP ₹159.1), but the weak quarterly earnings will likely cap gains.
📈 Long termThe long-term trajectory depends entirely on the API segment reaching 25-30% capacity utilization to stop the current cash burn of ~₹10 Cr per quarter.
⚠ Risk flags
- Persistent losses in the API segment
- High interest burden relative to operating cash flow
- Low capacity utilization in new business lines
Key Highlights
Consolidated revenue for Q1 FY27 stood at ₹48.71 Cr, up from ₹45.20 Cr in Q1 FY26.
API segment reported a loss of ₹8.04 Cr, significantly impacting the consolidated bottom line.
Promoter Sunil L Mundra to infuse ₹10 Cr via 1.25 lakh equity shares and 5 lakh warrants at ₹160/unit.
Interest costs increased to ₹4.97 Cr in Q1 FY27 from ₹3.99 Cr in the year-ago period.
Promoter shareholding of Sunil L Mundra expected to rise from 5.79% to 11.12% post-conversion.
👀 What to Watch
Investors should closely monitor the API segment's revenue growth; the company previously indicated a ₹100 Cr annual revenue target is needed for cash break-even, while current quarterly run-rates are significantly lower.
Rs 10 Cr Promoter Fundraise Approved Amid Q1 Net Loss of Rs 5.74 Cr
Natural Capsules Limited (NCL) reported a consolidated net loss of Rs 5.74 Cr for Q1 FY27, largely unchanged from the Rs 5.58 Cr loss in the same quarter last year. While total revenue grew 7.7% YoY to Rs 48.71 Cr, the API segment remains a major drag with a quarterly loss of Rs 8.04 Cr. To address liquidity, the board approved a Rs 10 Cr preferential issue of equity and warrants to the promoter at Rs 160 per share, which is slightly above the current market price. High interest costs of Rs 4.97 Cr continue to erode the profits generated by the core capsule business.
Confidence: HIGH
What changedThe company has moved to secure Rs 10 Cr in promoter funding to support operations as the API segment's commercial scale-up takes longer than expected.
Why it mattersThe promoter infusion at a premium to the current market price provides a liquidity cushion and signals confidence, but the business remains under pressure from high debt servicing costs and API-related losses.
Fundraise vs Market Cap: ~6.2%Q1 Consolidated Net Loss: ₹5.74 crAPI Segment Loss: ₹8.04 crPreferential Issue Price: ₹160Interest Cost (Q1): ₹4.97 cr
📅 Short termThe stock may see some support from the promoter's commitment to buy shares at Rs 160, but the weak quarterly earnings and widening API losses will likely limit any significant upside.
📈 Long termThe long-term outlook depends on the API division reaching 25-30% capacity utilization to stop the cash burn. Until the API segment breaks even, the company's overall profitability will remain suppressed.
⚠ Risk flags
- Persistent losses in the API segment
- High interest-to-EBITDA ratio
- Execution delays in scaling new HPMC capsule lines
Key Highlights
Consolidated net loss of Rs 5.74 Cr for Q1 FY27 vs a loss of Rs 5.58 Cr in Q1 FY26.
API segment revenue grew to Rs 5.69 Cr from Rs 0.96 Cr YoY, but segment losses widened to Rs 8.04 Cr.
Board approved a Rs 10 Cr fundraise through 1,25,000 equity shares and 5,00,000 warrants at Rs 160 each.
Interest expenses rose to Rs 4.97 Cr for the quarter, up from Rs 3.99 Cr in the year-ago period.
Promoter Sunil L Mundra's stake to potentially increase from 5.79% to 11.12% upon full warrant conversion.
👀 What to Watch
Investors should track the API segment's revenue trajectory toward the Rs 25 Cr per quarter (Rs 100 Cr annual) cash break-even target. The upcoming Extra Ordinary General Meeting on September 9, 2026, for shareholder approval of the fundraise is the next key milestone.
Natural Capsules FY26 Revenue Up 11% to ₹187.2 Cr; Posts Net Loss of ₹24.66 Cr on API Costs
Natural Capsules Limited reported a consolidated net loss of ₹24.66 crore for FY26, compared to a profit in the previous year, despite an 11% growth in revenue to ₹187.20 crore. The profitability was severely impacted by operational disruptions at the Puducherry plant and high pre-commercial overheads, depreciation, and interest costs from the new API subsidiary, Natural Biogenex. While Q4 FY26 showed a sequential recovery with revenue of ₹58.45 crore and a return to positive EBITDA (₹1.33 crore), the company faces significant liquidity pressure and is exploring fundraising through BIRAC schemes, preferential allotments, or rights issues.
Key Highlights
FY26 consolidated revenue grew 11% YoY to ₹187.20 crore, but EBITDA margins dropped from 10.35% to -0.83%.
Q4 FY26 revenue surged 55% QoQ to ₹58.45 crore, aided by clearing a backlog of deferred dispatches from the Puducherry facility.
Finance costs rose to ₹10.95 crore and depreciation to ₹17.14 crore as the Tumkur API facility entered its operational cycle.
Installed capsule capacity increased to 25 billion per annum, with the new HPMC line expected to contribute revenue in H2 FY27.
Management is targeting a return to consolidated profitability in FY27 through improved product mix and API commercialization.
👀 What to Watch
Investors should remain cautious as the company navigates a liquidity crunch and high debt servicing costs following its API expansion. Key triggers to watch include the successful execution of the proposed fundraising and the timely regulatory approval for HPMC capsule exports to the US market in H2 FY27.
Natural Capsules Q4FY26 Revenue Jumps 30% Y-o-Y to ₹58.45 Cr; Reports Net Loss of ₹4.98 Cr
Natural Capsules reported a strong sequential recovery in Q4FY26 with revenue growing 55% Q-o-Q to ₹58.45 crore, primarily driven by clearing deferred orders from the Puducherry plant. Despite the topline growth, the company posted a consolidated net loss of ₹4.98 crore for the quarter and a significant ₹24.66 crore loss for the full year FY26. Profitability was hampered by a 73% Y-o-Y increase in finance costs and an 88% rise in depreciation following heavy investments in the API segment. Management expects stability in FY27 as commercial API sales have commenced and a new HPMC capsule line is set to contribute from H2 FY27.
Key Highlights
Q4FY26 Revenue increased 30% Y-o-Y to ₹58.45 crore, supported by ₹36 crore in deferred dispatches from the previous quarter.
Consolidated EBITDA for the quarter stood at ₹1.33 crore, down 70% Y-o-Y, with margins compressing to 2.28%.
Full-year FY26 net loss widened to ₹24.66 crore from a profit of ₹0.62 crore in FY25 due to high operational and capital costs.
Total capsule manufacturing capacity reached 20.25 Billion Capsules per Annum (BCPA) with the addition of a new HPMC line.
Subsidiary Natural Biogenex entered a definitive agreement with Fermbox Bio for fermentation-based CDMO services to improve asset utilization.
👀 What to Watch
Investors should closely monitor the scaling of the API business and the margin profile of the new HPMC line starting H2 FY27. While revenue recovery is visible, the high debt servicing and depreciation costs necessitate a cautious approach until bottom-line breakeven is achieved.
Natural Capsules Q4 Revenue Up 55% QoQ to ₹58.45 Cr; API Commercial Sales Commence
Natural Capsules Limited reported a sequential recovery in Q4 FY26 with revenue of ₹58.45 Cr, up 55% QoQ, primarily due to clearing deferred dispatches from its Puducherry plant. Despite the quarterly improvement, the company ended FY26 with a net loss of ₹24.66 Cr and a negative EBITDA margin of 0.83%. A key positive is the commencement of commercial API sales and a new CDMO agreement with Fermbox Bio to boost fermentation asset utilization. Management expects a more stable FY27 with new HPMC capsule lines contributing in the second half.
Key Highlights
Q4 FY26 revenue grew 55% QoQ to ₹58.45 Cr, while EBITDA turned positive at ₹1.33 Cr.
Full-year FY26 revenue remained flat at ₹187.20 Cr with a substantial net loss of ₹24.66 Cr.
Commercial sales in the API segment finally began in Q4 FY26 after previous delays.
Signed a Framework and Contract Manufacturing Agreement with Fermbox Bio for fermentation-based CDMO.
New HPMC line for double-zero capsules is ready for production, targeting US markets in H2 FY27.
👀 What to Watch
Monitor the scale-up of the API segment and the impact of the Fermbox Bio partnership on asset utilization. The stock remains a watch until the company demonstrates consistent quarterly profitability and successful US market entry for its new capsule line.
Natural Capsules Approves FY26 Results, Appoints New CS, and Allots 25,000 ESOP Shares
Natural Capsules Limited has approved its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified auditor's opinion with a reported diluted EPS of Rs. 10.72. The company appointed Mr. Akshay Dutta as the new Company Secretary and Compliance Officer and re-appointed Mr. Laxminarayana Moondra as Whole-time Director for a three-year term. Additionally, the board allotted 25,000 equity shares under the ESOP 2025 plan, increasing the total paid-up share capital to Rs. 10.41 crore. These moves signify a focus on governance and leadership continuity.
Key Highlights
Approved audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion.
Appointed Mr. Akshay Dutta as Company Secretary and Compliance Officer effective May 27, 2026.
Allotted 25,000 equity shares of Rs. 10 each under ESOP 2025, increasing paid-up capital to Rs. 10,41,11,540.
Re-appointed Mr. Shri Laxminarayana Moondra as Whole-time Director for a 3-year term starting July 28, 2026.
Reported a diluted earnings per share (EPS) of Rs. 10.72 for the financial year 2025-26.
👀 What to Watch
Investors should monitor the full financial statements for FY26 to evaluate operational performance beyond the reported EPS. The management re-appointments and new compliance officer provide stability in corporate governance.
Natural Capsules Subsidiary Natural Biogenex to Raise ₹1.11 Crore via Rights Issue
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited, has approved a rights issue of 11,11,200 equity shares. The shares are priced at a face value of ₹10 each, resulting in a total fundraise of ₹1,11,12,000. This capital infusion is aimed at strengthening the subsidiary's financial position. Investors should note that this is a relatively small capital raise for a material subsidiary.
Key Highlights
Material subsidiary Natural Biogenex Private Limited to issue 11,11,200 equity shares
Issue price set at ₹10 per share (at par), totaling ₹1.11 crore
Board approval for the rights issue was granted on May 27, 2026
Disclosure made under Regulation 30(9) of SEBI (LODR) Regulations
👀 What to Watch
Monitor whether Natural Capsules Limited subscribes to its portion of the rights issue to maintain its stake. The small quantum suggests routine capital needs rather than a major strategic shift.
Natural Capsules Approves FY26 Results and Allots 25,000 Shares Under ESOP
Natural Capsules Limited held a board meeting on May 27, 2026, to approve audited financial results for the quarter and year ended March 31, 2026. The company approved the allotment of 25,000 equity shares following the exercise of vested employee stock options, realizing Rs. 2.50 lakh. Key leadership decisions included the re-appointment of Mr. Shri Laxminarayana Moondra as Whole-time Director for three years and the appointment of a new Company Secretary. The company's paid-up share capital has increased to Rs. 10.41 crore following this allotment.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Allotted 25,000 equity shares of Rs. 10 face value, increasing paid-up capital to Rs. 10,41,11,540.
Re-appointed Mr. Shri Laxminarayana Moondra as Whole-time Director for a 3-year term effective July 28, 2026.
Realized Rs. 2,50,000 from the exercise of ESOP options at an exercise price of Rs. 10 per share.
Reported a diluted earnings per share (EPS) of Rs. 10.72 for the financial year 2025-26.
👀 What to Watch
Investors should examine the detailed FY26 financial results to evaluate the company's operational performance. The management re-appointments and minor equity dilution from ESOPs are routine and should not significantly impact the stock price.
Natural Capsules Approves FY26 Results, Re-appoints WTD, and Allots 25,000 ESOP Shares
Natural Capsules Limited (NATCAPSUQ) held a board meeting on May 27, 2026, to approve the audited financial results for the quarter and full year ended March 31, 2026. The board confirmed the re-appointment of Mr. Laxminarayana Moondra as Whole-time Director for a three-year term and appointed Akshay Dutta as the new Company Secretary. Furthermore, the company allotted 25,000 equity shares under its ESOP plan, resulting in the paid-up share capital increasing to ₹10,41,11,540. The statutory auditors issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Re-appointed Mr. Laxminarayana Moondra as Whole-time Director for 3 years starting July 28, 2026.
Allotted 25,000 equity shares of ₹10 face value following the exercise of vested ESOP options.
Paid-up share capital increased from ₹10,38,61,540 to ₹10,41,11,540 post-allotment.
Appointed Mr. Akshay Dutta as Company Secretary and M/s. Mallya & Mallya as Internal Auditors for FY 2026-27.
👀 What to Watch
Investors should examine the detailed FY26 financial performance once released to evaluate the company's growth trajectory. The re-appointment of a promoter-director ensures management continuity, which is generally positive for stability.
Natural Capsules Approves FY26 Results, Re-appoints Director, and Allots 25,000 ESOP Shares
Natural Capsules Limited approved its audited financial results for the quarter and year ended March 31, 2026, during its board meeting on May 27, 2026. The company re-appointed Mr. Laxminarayana Moondra as Whole-time Director for a three-year term and appointed Mr. Akshay Dutta as the new Company Secretary. Furthermore, the board allotted 25,000 equity shares under the Employee Stock Option Plan 2025, raising the paid-up capital to Rs. 10.41 crore. The company reported a diluted earnings per share (EPS) of Rs. 10.72 for the 2025-26 financial year.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Allotted 25,000 equity shares of face value Rs. 10 each under ESOP 2025, realizing Rs. 2,50,000.
Paid-up share capital increased from Rs. 10,38,61,540 to Rs. 10,41,11,540 following the allotment.
Re-appointed Mr. Laxminarayana Moondra as Whole-time Director for a 3-year term effective July 28, 2026.
Reported a diluted earnings per share (EPS) of Rs. 10.72 for the financial year 2025-26.
👀 What to Watch
Investors should examine the full audited financial statements to evaluate the company's operational performance beyond the reported EPS. The re-appointment of key management indicates leadership stability, which is generally a positive sign for long-term stability.
Natural Capsules FY26 Results: Board Approves Financials, Allots 25,000 ESOP Shares
Natural Capsules Limited has approved its audited financial results for the fiscal year ended March 31, 2026, with the statutory auditor providing an unmodified opinion. The company allotted 25,000 equity shares under its ESOP 2025 plan, increasing the total paid-up share capital to Rs. 10.41 crore. Key management updates include the re-appointment of Mr. Laxminarayana Moondra as Whole-time Director for three years and the appointment of a new Company Secretary. The company reported a diluted earnings per share (EPS) of Rs. 10.72 for the financial year.
Key Highlights
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Allotted 25,000 equity shares of Rs. 10 each, increasing paid-up capital from Rs. 10.38 crore to Rs. 10.41 crore.
Reported a diluted earnings per share (EPS) of Rs. 10.72 for the 2025-26 financial year.
Re-appointed Mr. Laxminarayana Moondra as Whole-time Director for a 3-year term effective July 28, 2026.
Appointed Mr. Akshay Dutta as Company Secretary and Compliance Officer effective May 27, 2026.
👀 What to Watch
Investors should examine the full financial statements to evaluate revenue and margin trends, though the unmodified audit opinion and steady EPS provide a baseline of stability.
Natural Capsules Shareholders Approve Enhanced Investment & Loan Limits with 99.99% Majority
Natural Capsules Limited (NATCAPSUQ) has successfully passed a special resolution to enhance its limits for investments, loans, guarantees, and securities under Section 186 of the Companies Act. The resolution was approved via postal ballot with an overwhelming majority of 99.9962% votes in favor. This regulatory milestone provides the company with increased financial flexibility to support its growth objectives or subsidiary requirements. The voting process concluded on March 27, 2026, with strong participation from the promoter group and non-institutional public shareholders.
Key Highlights
Special Resolution passed to increase limits for investments, loans, and guarantees under Section 186 of the Companies Act.
The resolution received 99.9962% approval, with 5,296,294 votes in favor and only 201 votes against.
Promoter group participation was high at 99.61% of their holdings, with 100% of their polled votes in favor.
The approval grants the company greater headroom for capital deployment and inter-corporate financial support for future projects.
👀 What to Watch
The approval indicates strong shareholder trust in management's capital allocation strategy; investors should monitor future announcements for specific investments or expansion plans that utilize these new limits.
Natural Capsules Assigned IVR BB+ (Stable) Rating for Rs 59.15 Cr Debt Facilities
Natural Capsules Limited has received credit ratings from Infomerics Valuation and Rating Limited for bank facilities totaling Rs 59.15 crores. The rating agency assigned 'IVR BB+' with a Stable outlook for long-term facilities worth Rs 56.35 crores and 'IVR A4+' for short-term facilities of Rs 2.80 crores. These ratings reflect the company's current creditworthiness across various loan instruments from lenders like SBI and HDFC Bank. The stable outlook suggests that the rating is unlikely to change in the near term.
Key Highlights
Total bank facilities rated at Rs 59.15 crores across multiple lenders.
Long-term facilities of Rs 56.35 crores assigned IVR BB+ rating with a Stable outlook.
Short-term facilities of Rs 2.80 crores assigned IVR A4+ rating.
Major debt exposure includes HDFC Bank (Rs 28.15 Cr) and State Bank of India (Rs 25.30 Cr) for term loans and cash credit.
👀 What to Watch
The BB+ rating is considered speculative grade (just below investment grade), indicating moderate credit risk. Investors should monitor the company's financial performance for potential upgrades to investment-grade status (BBB- or higher) which could lower future borrowing costs.
Natural Capsules Subsidiary Signs ₹60 Cr Strategic CDMO Agreement with Fermbox Bio
Natural Biogenex, a material subsidiary of Natural Capsules Limited, has entered into a strategic framework agreement with Fermbox Bio to bolster fermentation-based CDMO capabilities. As part of the deal, Fermbox will provide equipment worth up to ₹60 crore at NBPL's Tumkur facility. This collaboration enables the company to target global biopharma and industrial biotech clients using advanced fermentation technology. The partnership is strategically timed to benefit from India's BioE3 Policy and the growing global demand for outsourced biomanufacturing.
Key Highlights
Natural Biogenex (NBPL) signs definitive agreements with Fermbox Bio for fermentation-based CDMO services.
Fermbox Bio to provide advanced equipment placement and technology worth up to ₹60 crore at NBPL’s Tumkur plant.
NBPL will handle GMP-compliant manufacturing, quality assurance, and regulatory compliance for the partnership.
The collaboration targets high-value segments in both pharmaceutical and industrial biotechnology.
The move aligns with the Indian government's BioE3 Policy to accelerate biomanufacturing innovation.
👀 What to Watch
Investors should view this as a significant value-accretive step into high-margin CDMO services. Monitor the operationalization of the ₹60 crore equipment and the subsequent impact on the subsidiary's order book and margins.
